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1. INTRODUCTION 
1.1. Mutations of the renin-angiotensin system genes and renal scarring in 
primary vesicoureteral reflux 
Primary vesicouretcric reflux (VUR) is a common familial disorder, but 
its genetic background has not been clarified. Primary VUR appears to be a 
dominant disorder with incomplete penetrance and variable expression. 
Previous studies have suggested a urinary tract malformation locus on 
chromosome 6p on the basis of a balanced translocation which was found in a 
patient with multicystic renal dysplasia and linkage of VUR families to HLA 
markers on 6p. VUR can be a part of a complex syndrome such as the renal-
coloboma syndrome, which is caused by mutations of PAX2 on chromosome 
lOq. In the first genomwide search of VUR no significant linkage was found 
to the previously reported VUR candidate loci, including 6p and lOq. 
Whereas a 20 cM locus on the short arm of the chromosome 1 was identified 
as a possible locus of primary VUR with a number of candidate genes. 
Reflux nephropathy (RN) is defined by the presence of renal scars in 
children with VUR. Renal scarring secondary to VUR. which is called RN, 
has been affected by genetic and environmental factors. It has been reported 
that adequate medical management of urinary tract infections (UTI) and 
follow-up of children with VUR could significantly reduce the incidence of 
nephropathy. RN is an important cause of hypertension, and chronic renal 
failure (CRF) in children. RN accounts for up to 25 % of children and young 
adults with CRF. Shimada ct al reported that most children who developed 
renal insufficiency due to RN have either two small kidneys or one small 
kidney and a contralateral large kidney with severe scars. Mackie and 
Stephens proposed that renal dysplasia and/or hypoplasia related to abnormal 
development of the embryonic ureteral bud, was the basis for some pathology 
associated vesicoureteral reflux (VUR). Current knowledge indicates that the 
evolution of VUR is not equal in all patients, suggesting the influence of 
different factors including genetics. The RAS has been postulated to play an 
important role in the regulation of glomerular sclerotic processes as well as in 
renal development. Thus, genes encoding components of the RAS have 
attracted much interest as risk factor of renal scarring. The insertion/deletion 
(I/D) polymorphism in the angiotensin-converting enzyme (ACE) gene is 
located on chromosome 17. Three possible genotypes are determined by the 
absence (deletion, D) or presence (insertion, I) of a 287-base pair DNA 
fragment at intron 16: DD, ID, II. The deletion allele is associated with 
higher ACE plasma levels. An association between I/D polymorphism of the 
angiotensin converting enzyme (ACE) and scar formation in different 
nephropathies (IgA nephropathy, diabetic nephropathy, autosomal dominant 
polycystic kidney disease, focal glomerulosclerosis and finally, reflux 
nephropathy) were reported. Generally the DD genotype of ACE was 
correlated with the development of the diseases or the decline of renal 
function in these pathological states. Other gene polymorphisms of the RAS 
such as the M235T polymorphism of the angiotensinogen (ATG) gene or the 
A1166C polymorphism of the angiotensin II type 1 receptor (ATI) gene are 
supposed to be involved in renal scar formation. 
Platelet aggregation, blood viscosity and serum lipids in hypertensive 
and obese children 
In human essential hypertension, endothelial dysfunction has been 
documented in peripheral and coronary macro- and microcirculation and in 
renal circulation. The mechanism appears to be the activation of an 
alternative pathway involving cyclooxigenase, which reduces NO availability 
through production of oxidative stress. Reduced NO availability can increase 
the biological activity of endothelin-1 (ET-1). Besides the endothelial 
damage platelet hyperactivity may also play a role in the vascular 
complications of essential hypertension. Nitric oxide not only causes vessel 
relaxation but also inhibits platelet aggregation, smooth 
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Musclecell proliferation, monocyte adhesion, adhesion molecules expression, 
and ET-1 production which is a potent vasoconstrictor and has inotropic a 
mitogenic properties. 
During hypertension very important alterations have been shown in 
Theological, mechanical and biochemical characteristics of erythrocytes and 
of blood flow. In hypertensive adults Cicco et al found a decrease in 
erythrocyte deformability, in erythrocyte aggregation time, an increase of 
shear rate to disaggregate erythrocytes and in fibrinogenaemia, a decrease in 
cellular oxygen delivery and tissue oxygenation and an impairment of 
microcirculation. These patterns were not related with the age of the patients 
but with the patient hypertension age. Carroll et al demonstrated that obesity 
and poor cardio respiratory fitness might be important in the development of 
haemorheological abnormalities associated with metabolic syndrome. 
Increased plasma viscosity is associated with the increased clustering of 
metabolic markers in middle-aged people. 
Most of non-genetic predisposing factors for adult essential hypertension 
- like smoking, atherosclerosis, hyperlipidemia, diabetes, and alcohol 
consumption - are absent in paediatric population. Therefore the pathogenetic 
role of platelets, nitric oxide, and endothelin can be more precisely 
investigated in adolescent hypertensive patients. Nevertheless the occurrence 
of obesity in the general and also in paediatric population has been 
extensively growing, and its role in juvenile essential hypertension (JEHT) 
has not been cleared yet. 
In our previous study platelet aggregation and the thromboxane B2 (TxB2) 
level were significantly higher while the plasma total cholesterol, triglyceride 
and LDL cholesterol concentrations were normal in non-obese children with 
JEHT. Obesity and hypertension are double risks for cardiovascular 
morbidity in adults. Beside high blood pressure, platelet aggregation, blood 
and plasma viscosity, plasma lipid concentrations and endothelial nitric oxide 
(NO) production are frequently investigated factors in adult hypertension. 
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1.3. The effects of vitamin E on uraemic erythrocytes in the early period of 
erythropoietin treatment 
Anaemia is a common feature of chronic renal failure (CRF), particularly 
with chronic haemodialysis (HD), and causes a significant morbidity. An 
erythropoietin (EPO) deficiency and hypoproliferative bone marrow are the 
principal factors of the anaemia. A further important contributory 
phenomenon is the shortened red blood cell (RBC) survival, which may be 
due to circulating plasma factors accumulating during the uraemic state. 
Additionally, a growing body of evidence has accumulated indicating that a 
disturbance of the balance between oxidative stress and antioxidant defence 
mechanisms plays a major role in the pathomechanism of oxidative 
haemolysis of chronic uraemic patients undergoing chronic HD therapy. The 
plasma lipid peroxidation, malonyl dialdehyde (MDA) production and 
haemoglobin (Hb) oxidation are increased, and the activities of antioxidant 
enzymes [superoxide dismutase (SOD), catalase (Cat) and glutathione 
peroxidase (Gpx)] are decreased. The vitamin E concentration in the 
erythrocytes is low and vitamin C is depleted during HD. The increased 
MDA production results in changes in cation permeability and a reduced 
deformability of the RBCs. During HD therapy the availability of free 
oxygen radicals (FOR) originating from activated neutrophils is increased. 
The production of reduced glutathione (GSH), one of the main scavenging 
materials of FOR, is decreased. Furthermore, the activity of the RBC hexose 
monophosphate shunt, which is responsible for GSH regeneration from 
oxidized glutathione (GSSG), is depressed. All these factors make the free 
radical scavenging system ineffective. \ 
In a previous paper we reported on the early effect of rh EPO therapy on 
the changes in the glutathione redox system and Hb oxidation causing 
haemolysis in 10 children with CRF undergoing chronic HD. A rapid 
increase in the reticulocyte count was accompanied by a slower rise in total 
Hb concentration. The mean level of GSSG was increased from I3.2±5.3 
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nmol/g Hb to 56.7±I5.8 nmol/g Hb 4 weeks after the start of rh EPO 
(p<0.001), followed by a fall to the basal value. The GSH levels showed a 
smaller though constant elevation during rh EPO therapy (pcO.OOl). Before 
rh EPO treatment, incubation of RBCs for I h with acetylphenylhydrazine 
induced a decrease in GSH concentration as compared with the controls 
(pcO.OOl), which became more pronounced in the first few weeks of rh EPO 
therapy (p<0.001). In addition, the levels of Hb derivatives (metHb and 
haemichrome) increased in the first 4 weeks of rh EPO treatment (pcO.OOl). 
Although there was no significant difference between the values before and 
during EPO treatment, the MDA levels were continuously higher and the 
SOD, Cat and Gpx activities were lower than in the control (pcO.OOl). These 
results were compatible with oxidative damage to the RBCs in the early 
period of rh EPO therapy in children with end-stage renal failure. The GSH-
GSSG system as an important cellular defence mechanism of the RBCs 
appears to be severely affected. 
2. AIMS OF THE STUDY 
The objectives of this study were to investigate 
2.1. Mutations of the renin-angiotensin system genes and renal scarring in 
primary vesicoureteral reflux 
2.1.1. Is there any role of ACE gene 1/D polymorphism in the occurrence of VUR? 
2.1.2. Is there any difference in the M235T polymorphism of the angiotensinogen 
(ATG) gene between VUR patients and controls? 
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2.1.3. Is there any contribution of Al I66C polymorphism of the angiotensin II type 
I receptor (ATI) gene to the development of primary VUR? 
2.1.4. Do these ACE, ATG and ATI gene mutations contribute to the progression 
of VUR associated renal scarring? 
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2.2. Platelet aggregation, blood viscosity and serum lipids in hypertensive 
and obese children 
2.2.1. How obesity and hypertension can separately and in combination influence 
platelet aggregation, blood and plasma viscosity in children? 
2.2.2. Are there any changes in plasma lipid levels in obese (O) and obese 
hypertensive (OHT) patients at this age? 
2.2.3. How endothelial NO change in essential hypertension (EHT), O and OHT as 
compared with the controls. 
2.3. The effects of vitamin E on uraemic erythrocytes in the early period of 
erythropoietin treatment 
2.3.1. The aim of the present study was to investigate the effects of vitamin E on the 
glutathione redox system. 
2.3.2. We studied the effect of vitamin E and erythropoietin combined therapy on 
the Hb oxidation and the changes in haematocrit (Htc) and Hb in the same 
patients. 
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3. PATIENTS 
3.1. Mutations of the renin-angiotensin system genes and renal scarring in 
primary vesicoureteral reflux 
77 children with VUR and 80 healthy controls were studied. 38 patients had 
low grade (I III) VUR and 39 patients had high grade (IV-V) or severe VUR. 
Renal scarring was found with WmTc-DMSA scan in 43 VUR patients. 
3.2. Platelet aggregation, blood viscosity and serum lipids in hypertensive 
and obese children 
32 patients (mean age: 14.4±3.1 years, male/female 17/18) with juvenile 
essential hypertension (JEHT) 17 of them with >25 body mass index (BMI 
kg/m2 obese hypertension, OHT), 15 with <25 BMI (essential hypertension, 
EHT) and 35 age and sex matched controls (15 with >25 BMI (obese, O) and 
20 with <25 BMI, C) were investigated. 
3.3. The effects of vitamin E on uraemic erythrocytes in the early period of 
erythropoietin treatment 
This study included 10 children with chronic renal failure (5 boys and 5 girls, 
age range 7-17 years). The patients had been on 4-h bicarbonate hemodialysis 
(HD) (3 times a week) for 2-6 years. Following 1 year of rh EPO therapy 
(supported by CILAG) 4 weeks break was introduced because of a lack of 
further supply by the National Insurance Company. From the restart of 
rhEPO treatment the same dosage was used but from the 3rd week the 
treatment was completed with vitamin E. 
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4. METHODS 
4.1. Mutations of the renin-angiotensin system genes and renal scarring in 
primary vesicoureteral reflux 
Genomic DNA was isolated from peripheral blood leucocytes by a standard 
phenol/chloroform method. The I/D polymorphism in intron 16 of the ACE 
gene was determined according to the previously method of Chiu et al. using 
polymerase chain reaction. 
The M235T polymorphism in exon 2 of the ATG gene was detected by 
single-step LightCycler technology published by Malin et al. 
Determination of the A1166C polymorphism of the ATI gene was also 
carried out with LightCycler technology according to the detection of the 
M235T polymorphism, which was optimized for the analysis of AI166C 
polymorphism by us. 
4.2. Platelet aggregation, blood viscosity and serum lipids in hypertensive 
and obese children 
Platelet aggregation was carried out with a laser rheoaggrcgometer using 
collagen stimulation at a linal concentration of 2 pg/ml platelet rich plasma 
by the method of Jung et al. 
Measurement of whole blood and plasma viscosity was carried out in a 
Hevimet-40 viscosimeter. 
Nitric oxide end-products in the plasma were determined as nitrite and nitrate 
imultaneously by anion-exchange HPLC. 
Plasma lipid peroxides were quantified as malondialdehyde (MDA)-
thiobarbituric acid adducts by HPLC. 
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Plasma free thiol (SH) groups were assayed with 5.5-dithiobis (2-
riitrobenzoic acid) at 412 nm. 
Plasma cholesterol and triglicerides were assayed using standard methods. 
4.3. The effects of vitamin E on uraemic erythrocytes in the early period of 
erythropoietin treatment 
GSH and GSSG determinations were carried out after hemolysis of two 
samples of whole blood collected with EDTA by the method of Tietze. 
Carbonmonoxide-Hb (COHb), as an indirect measure of hemolysis, was 
estimated in heparinized blood with a hemoximeter (Radiometer 
Copenhagen. Denmark) and expressed as a percentage of the total Hb. 
5. RESULTS 
5.1. Mutations of the renin-angiotensin system genes and renal scarring in 
primary vesicoureteral reflux 
We found the significant over-representation of the DD genotype in patients 
with renal scarring (44%) compared to normal controls (22.5%; P<0.05) and 
patients with no scar formation (21%; P<0.05). A significantly higher D and 
significantly lower I allele frequencies were presented in VUR patients with 
scarred kidneys (D allele: 0.64 and I allele: 0.36) compared to controls (D 
allele: 0.53 and I allele: 0.47; P<0.05) and patients with unscarred kidneys (D 
allele: 0.4 and I allele: 0.6; P<0.05). No differences in the ATG and ATI 
genotype distributions and allele frequencies were observed in VUR patients 
compared to normal population. The DD genotype and D allele of ACE may 
be a genetic susceptibility factor contributing to scar formation in VUR. 
There is no linkage of genetic polymorphisms of ATG and ATI to VUR and 
VUR associated renal scarring. 
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5.2. Platelet aggregation, blood viscosity and serum lipids in hypertensive 
and obese children 
The plasma cholesterol was significantly higher in OHT and O groups as 
compared to C and trigliceridc was higher in OHT also (p<0.05). In vitro 
platelet aggregation was significantly higher in OHT, EHT and O as 
compared to controls (pcO.OOl). A significant positive correlation was 
observed between the BMI values and the platelet aggregation (r=0.47, 
p<:0.05). NO level was significantly lower in EHT and OHT as compared to 
controls (pcO.Ol). A significant negative correlation was observed between 
the results of platelet aggregation and NO levels (r=-0.53 and -0.504 for EHT 
and OHT groups respectively). Plasma MDA was significantly high in OHT, 
and free thiols were low in OHT (pcO.OOl) and EHT groups (pcO.Ol). Blood 
viscosity was higher in OHT (pcO.Ol), and plasma viscosity was higher in 
OHT (pcO.Ol) and O (pc0.05) as compared to controls. 
5.3. The effects of vitamin E on uraemic erythrocytes in the early period of 
erythropoietin treatment 
The Hb concentration was significantly higher than the initial level 2 weeks 
after the introduction of vitamin E. A significant rise in Hb level was 
observed only in the 8th week, when they were treated with rh EPO alone. Rh 
EPO + vitamin E resulted in a more rapid increase in the Htc too, which was 
significant in the 4lh week (2 weeks after the start of vitamin E), as compared 
with only the 5lh week with rh EPO alone. The mean level of oxidized 
glutathione increased from 10.9+3.1 nmol/g Hb (x±SD) to 26.7+5.7 nmol/g 
Hb 2 weeks after the start of rh EPO, but decreased significantly 1 week after 
vitamin E introduction, 10.1+4.9 ntnol/gHb (pcO.OOI), and remained at this 
level subsequently. The reduced glutathione (GSH) level displayed a smaller 
elevation (pc0.05), but was also decreased significantly I week after the 
introduction of vitamin E (pc0.05). Similar changes were observed in the 
percentages of carboxy Hb and met Hb (pcO.Ol). 
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6. CONCLUSIONS 
6.1.1. There was a significant over-representation of the DD genotype in patients 
with renal scarring compared with normal controls and patients with no scar 
formation. -r. . 
6.1.2. Significantly higher D and significantly lower I allele frequencies were 
present in VUR patients with scarred kidneys compared with controls and 
patients with unscarred kidneys. The DD genotype and D allele of ACE may 
be a genetic susceptibility factor contributing to scar formation in VUR. 
6.1.3. No differences in the ATG and ATI genotype distributions and allele 
frequencies were observed in VUR patients compared with the normal 
population. We detected no linkage of genetic polymorphism of ATG and 
ATI to VUR and VUR-associqated renal scarring. 
6.2.1. Obese children (hypertensive and controls) had significantly higher 
concentrations of total cholesterol and triglicerides. 
6.2.2. The levels of high density lipoprotein (HDL)-cholesterol were lower in obese 
hypertensive children than their non-obese counterparts. 
6.2.3. There was a significant increase in platelet aggregation and a decrease in NO 
levels in hypertensive patients (obese and non-obese) reflecting a significant 
negative correlation. An increased tendency to aggregation was also evident 
in obese normotensive patients. A significant positive correlation was 
observed between the platelet aggregation and BMI. 
6.2.4. Plasma free thiols were decreased in hypertensive children independent of 
their BMI. 
1 4 
6.2.5. An increased lipid peroxidation and higher blood and plasma viscosity were 
found only in obese patients with hypertension. 
6.2.6. Multivariate analysis revealed significant interactions in the effects of obesity 
and hypertension on platelet aggregation and thiol oxidation. In obese 
children an increased platelet aggregation and oxidative insult contribute to 
the development of hypertension and to the promotion of vascular damage. 
6.3.1. In uremic children with chronic haemodialyisis the rhEPO and vitamin E 
combined therapy resulted in a significant decrease in the high ratio of 
GSSG/GSH concentration indicating an oxidative stress at the beginning of 
rhEPO therapy. 
6.3.2. The level of COHB also decreased following the introduction of vitamin E 
during rhEPO treatment. This indicates a hemolysis that could be prevented 
by vitamin E. 
6.3.3. A significant increase in Hb and hematocrit was achieved within 2 weeks of 
starting the combined therapy, while similar results occurred only at 8lh and 
5lh weeks without vitamin E. Antioxidant vitamin E supplementation 
improved the therapeutic effect of rhEPO in patients with chronic renal 
failure on hemodialysis. 
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